Federal Circuit Affirms Noninfringement Ruling in Actelion-Mylan Hypertension Drug Patent Dispute

The U.S. Court of Appeals for the Federal Circuit issued a precedential decision affirming that Mylan Pharmaceuticals查看公司主页' generic hypertension (搜索)搜索该疾病 drug does not literally infringe Actelion Pharmaceuticals (搜索)搜索该词条' patents for Veletri查看药品详情®, a significant ruling that underscores the critical importance of scientific measurement conditions in pharmaceutical patent litigation.

Patent Dispute Over pH Requirements

Actelion owns U.S. Patent Nos. 8,318,802 and 8,598,227 covering pharmaceutical compositions involving epoprostenol查看药品详情. Each independent claim requires a bulk solution pH of "13 or higher" or "greater than 13." The dispute arose after Mylan submitted its Abbreviated New Drug Application (ANDA) to the FDA, prompting Actelion to sue for patent infringement.

Mylan argued that its generic drug was "manufactured from a bulk solution with a pH outside the patents' claims." The central issue became how to interpret the pH measurement requirements in the patent claims.

Critical Claim Construction Decision

The district court initially construed the claims to mean a pH of 12.5 or higher due to rounding rules, but the Federal Circuit remanded in 2023, explaining that "the proper claim construction cannot be reached without the aid of extrinsic evidence." On remand, the district court determined that pH of 13 or higher should be construed to mean a pH of 12.98 or higher, measured at standard temperature.

It was undisputed that Mylan's bulk solution has a pH well below 12.98. However, Actelion argued that when refrigerated, as indicated in the ANDA manufacturing process, "if measured at that cold temperature, has a pH of above 13."

Federal Circuit's Analysis

Judge Taranto authored the Federal Circuit opinion, which found that the district court properly construed the claim phrase "formed from a bulk solution having a pH of 13 or higher." The court's analysis relied on both intrinsic and extrinsic evidence.

Regarding intrinsic evidence, the claim language alone did not resolve the proper interpretation of "a pH of 13 or higher." The specification favored the district court's construction in its definition of "an alkaline environment" as one with "pH>7," which "undisputedly is accurate only at standard temperature."

The court held that extrinsic evidence, including the USP, general chemistry textbooks, and expert statements, showed "that those skilled in making pharmaceutical compositions, when referring to pH, mean a measurement at standard temperature unless they indicate otherwise."

Doctrine of Equivalents Barred

Actelion also argued that Mylan's manufacturing process was equivalent to its patented product because it "performs the same function (improved manufacturing stability) to achieve the same result (composition stability) in the same way (reducing hydrogen ion concentration) as the claimed invention."

The Federal Circuit rejected this argument, finding that Actelion was estopped from asserting equivalents theory because it narrowed its claims during prosecution. The court explained that because Actelion narrowed its claims during prosecution, it was estopped "from later arguing that the subject matter covered by the original, broader claim was nothing more than an equivalent."

Prosecution History Estoppel Application

The district court found that Actelion amended the pH limitation from reciting "greater than 12" to "13 or higher" to overcome the examiner's obviousness rejections. This constituted a narrowing claim amendment that estopped Actelion from asserting the doctrine of equivalents to cover pH values below 13.

Actelion argued that its claim amendment fell within the "tangentiality exception," but the Federal Circuit disagreed. The court held that "the prosecution history demonstrates that the examiner viewed pH 13 as the threshold for which unexpected results, necessary for nonobviousness here, had been shown."

Disclosure-Dedication Rule

The Federal Circuit also applied the disclosure-dedication rule, which independently barred Actelion from asserting an equivalents theory. Actelion contended that the rule should not apply because the disclosed alternative pH ranges "are not mutually exclusive with each other," but the court rejected this argument.

The Federal Circuit held that the disclosure-dedication rule "does not require that the disclosed alternatives be mutually exclusive; overlapping alternatives are readily susceptible of being clearly disclosed and yet partially unclaimed."

Implications for Pharmaceutical Patent Litigation

This decision reinforces several key principles in pharmaceutical patent litigation. The ruling demonstrates how scientific measurement conditions can significantly affect infringement outcomes, particularly in cases involving precise chemical or physical parameters.

The case also underscores the continued importance of prosecution history estoppel and the disclosure-dedication rule in limiting doctrine of equivalents arguments. Patent litigants must carefully evaluate whether the prosecution history and specification may constrain their ability to assert infringement under the doctrine of equivalents.

The Federal Circuit's analysis emphasizes that claim construction remains the critical first step in infringement analysis, particularly in ANDA litigation where technical specifications often determine the outcome of patent disputes.